This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Articles

Predictors of Response to Sertraline Treatment of Severe Premenstrual Syndromes

Ellen W. Freeman, Steven J. Sondheimer, Marcia Polansky, and Beatriz Garcia-Espagn

Published: August 31, 2000

Article Abstract

Background: Serotonergic antidepressantmedications have demonstrated efficacy in the treatment of severepremenstrual syndrome (PMS) and premenstrual dysphoric disorder(PMDD). Over 60% of subjects responded well to sertralinetreatment for PMS and PMDD in double-blind controlled studies.However, no studies have evaluated the predictors of treatmentresponse for this disorder. The current study examinedpretreatment demographic, medical history, and clinical symptompredictors of sertraline response in PMS and PMDD treatment.

Method: Sixty-two subjects diagnosed with severePMS (according to the Daily Symptom Report and global ratings offunctional impairment) or PMDD (DSM-IV) received sertralinetreatment as part of a randomized, double-blind,placebo-controlled treatment efficacy study. All subjectscompleted 3 screening cycles, including a single-blind placebowashout cycle, prior to 3 cycles of double-blind treatment.Outcome was assessed across the domains of PMS symptoms andquality of life. Demographic, medical history, and symptomvariables were used to predict sertraline response.

Results: Baseline postmenstrual symptom ratingswere significantly and independently associated withposttreatment PMS symptoms in multivariate analysis. Premenstrualand postmenstrual ratings of depression, medical historyvariables, and demographic variables were not significantlypredictive of response to sertraline.

Conclusion: Baseline postmenstrual symptomratings controlled for baseline premenstrual symptoms wereassociated with PMS symptoms at sertraline treatment endpoint.The findings suggest that non-menstrual-related baselinecharacteristics other than depression may influence sertralinetreatment outcome in patients with higher postmenstrual symptomlevels.

Volume: 61

Quick Links: Depression (MDD) , Premenstrual Dysphoric Disorder

Continue Reading…

Subscribe to read the entire article

$40.00

Buy this Article as a PDF

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...